Alopecia Areata

Immunology·MeSH: Alopecia Areata

Prevalence

200.0 / 100K

Incidence

20.0 / 100K/yr

16 drugs in development·11 companies·10 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(2)

Drug	Company
amlitelimab	Sanofi (SNY)
Amlitelimab	Sanofi (SNY)

Phase 2(7)

Drug	Company
bempikibart	Q32 Bio Inc. (QTTB)
eq101	Equillium, Inc. (EQ)
fb-102	Forte Biosciences, Inc. (FBRX)
fb102	Forte Biosciences, Inc. (FBRX)
ly4005130	ELI LILLY & Co (LLY)
Rezpegaldesleukin	NEKTAR THERAPEUTICS (NKTR)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(4)

Drug	Company
AQST-108	Aquestive Therapeutics, Inc. (AQST)
ARQ-252	Arcutis Biotherapeutics, Inc. (ARQT)
ARQ-255	Arcutis Biotherapeutics, Inc. (ARQT)
hcw9302	HCW Biologics Inc. (HCWB)

BioSniper tracks 16 drugs in development for Alopecia Areata across 11 companies.

There are 10 clinical trials targeting Alopecia Areata tracked by BioSniper.

The estimated prevalence of Alopecia Areata is approximately 200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.